Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Gliosarcoma 2Glioblastoma 2Recurrence 1Oligodendroglioma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cisplatin 3Cetuximab 3pembrolizumab 2zalutumumab 1temsirolimus 1osimertinib 1cobimetinib 1Taxes 1Sorafenib 1Radiotherapy 1Pemetrexed 1Paclitaxel 1Nivolumab 1Injections 1Fluorouracil 1Cilengitide 1Carboplatin 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Squamous Cell × Cilengitide × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡